A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice

Amir A Jazaeri, Robert Coleman, Anil K Sood, Michael Frumovitz, Pamela Therese Soliman, Aaron Shafer, Jeffry J. Cutrera, Marlana Klinger, Sara E. Sharafi, Cynae A.L. Johnson, Valerie F. Villanueva, Emily M. Hinchcliff, Andrea Dickens, Katherine E. Cain, Jaime E. Anderson, Karen H Lu, Shannon Neville Westin

Research output: Contribution to journalReview article

Abstract

The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.

LanguageEnglish (US)
Pages374-380
Number of pages7
JournalGynecologic oncology
Volume151
Issue number2
DOIs
StatePublished - Nov 1 2018

Fingerprint

Immunotherapy
Pharmaceutical Preparations
Neoplasms
Therapeutics
Clinical Trials

Keywords

  • Adoptive cell therapy
  • Checkpoint inhibitor
  • Clinical trials
  • Immune-related adverse events
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. / Jazaeri, Amir A; Coleman, Robert; Sood, Anil K; Frumovitz, Michael; Soliman, Pamela Therese; Shafer, Aaron; Cutrera, Jeffry J.; Klinger, Marlana; Sharafi, Sara E.; Johnson, Cynae A.L.; Villanueva, Valerie F.; Hinchcliff, Emily M.; Dickens, Andrea; Cain, Katherine E.; Anderson, Jaime E.; Lu, Karen H; Westin, Shannon Neville.

In: Gynecologic oncology, Vol. 151, No. 2, 01.11.2018, p. 374-380.

Research output: Contribution to journalReview article

Jazaeri, Amir A ; Coleman, Robert ; Sood, Anil K ; Frumovitz, Michael ; Soliman, Pamela Therese ; Shafer, Aaron ; Cutrera, Jeffry J. ; Klinger, Marlana ; Sharafi, Sara E. ; Johnson, Cynae A.L. ; Villanueva, Valerie F. ; Hinchcliff, Emily M. ; Dickens, Andrea ; Cain, Katherine E. ; Anderson, Jaime E. ; Lu, Karen H ; Westin, Shannon Neville. / A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. In: Gynecologic oncology. 2018 ; Vol. 151, No. 2. pp. 374-380.
@article{37e555586f7c40e5bf7de43e88637e87,
title = "A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice",
abstract = "The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.",
keywords = "Adoptive cell therapy, Checkpoint inhibitor, Clinical trials, Immune-related adverse events, Immunotherapy, Targeted therapy",
author = "Jazaeri, {Amir A} and Robert Coleman and Sood, {Anil K} and Michael Frumovitz and Soliman, {Pamela Therese} and Aaron Shafer and Cutrera, {Jeffry J.} and Marlana Klinger and Sharafi, {Sara E.} and Johnson, {Cynae A.L.} and Villanueva, {Valerie F.} and Hinchcliff, {Emily M.} and Andrea Dickens and Cain, {Katherine E.} and Anderson, {Jaime E.} and Lu, {Karen H} and Westin, {Shannon Neville}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2018.08.037",
language = "English (US)",
volume = "151",
pages = "374--380",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice

AU - Jazaeri, Amir A

AU - Coleman, Robert

AU - Sood, Anil K

AU - Frumovitz, Michael

AU - Soliman, Pamela Therese

AU - Shafer, Aaron

AU - Cutrera, Jeffry J.

AU - Klinger, Marlana

AU - Sharafi, Sara E.

AU - Johnson, Cynae A.L.

AU - Villanueva, Valerie F.

AU - Hinchcliff, Emily M.

AU - Dickens, Andrea

AU - Cain, Katherine E.

AU - Anderson, Jaime E.

AU - Lu, Karen H

AU - Westin, Shannon Neville

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.

AB - The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.

KW - Adoptive cell therapy

KW - Checkpoint inhibitor

KW - Clinical trials

KW - Immune-related adverse events

KW - Immunotherapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85053038160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053038160&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2018.08.037

DO - 10.1016/j.ygyno.2018.08.037

M3 - Review article

VL - 151

SP - 374

EP - 380

JO - Gynecologic Oncology

T2 - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -